Samsung Biologics has become one of the world’s fastest-growing contract development and manufacturing organizations (CDMOs). Founded in 2011, the South Korean biotechnology company has rapidly expanded from a single manufacturing facility into the world’s largest biologics manufacturing campus, serving many of the world’s leading pharmaceutical companies.
The company’s growth is being fueled by rising global demand for biologics, biosimilars, antibody-drug conjugates (ADCs), and cell & gene therapies. As pharmaceutical companies increasingly outsource manufacturing, Samsung Biologics continues to secure large commercial contracts while expanding its production footprint across Asia and North America.
Latest Financial Performance (FY2025)
Samsung Biologics delivered its strongest financial performance in company history during fiscal year 2025.
Revenue reached KRW 4.557 trillion (approximately USD 3.3 billion), representing 30.3% year-over-year growth. Operating profit climbed to KRW 2.069 trillion, increasing 56.6% from 2024, while EBITDA reached KRW 2.439 trillion, reflecting strong operational efficiency and high plant utilization. The company expects 15–20% revenue growth in 2026, supported by Plant 5, expanding global contracts, and increasing outsourcing demand.
Samsung Biologics Financial Report
| Financial Metric | FY2024 | FY2025 | YoY Growth |
|---|---|---|---|
| Revenue | KRW 3.497 Trillion | KRW 4.557 Trillion | 30.3% |
| Operating Profit | KRW 1.321 Trillion | KRW 2.069 Trillion | 56.6% |
| EBITDA | KRW 1.622 Trillion | KRW 2.439 Trillion | 50.4% |
| Q4 Revenue | KRW 950.3 Billion | KRW 1,285.7 Billion | 35.3% |
| Q4 Operating Profit | KRW 314.7 Billion | KRW 528.3 Billion | 67.9% |
2026 Performance Indicates Continued Momentum
The company’s first-quarter 2026 results indicate that growth remains strong.
Samsung Biologics reported Q1 2026 revenue of KRW 1.257 trillion and operating profit of KRW 580.8 billion, driven by full utilization of Plants 1–4, increasing customer demand, and continued commercial manufacturing activities. Cumulative contract value has now exceeded USD 21.4 billion, highlighting sustained demand from global pharmaceutical companies.
Product and Service Portfolio
Unlike traditional pharmaceutical companies, Samsung Biologics does not generate revenue primarily from selling branded medicines. Instead, its business is centered on providing end-to-end manufacturing services for biotechnology companies.
Major Product Lines
| Business Segment | Key Products & Services |
|---|---|
| Contract Development (CDO) | Cell line development, process development, analytical development |
| Drug Substance Manufacturing | Monoclonal antibodies (mAbs), recombinant proteins, biosimilars |
| Drug Product Manufacturing | Vial filling, prefilled syringes, sterile injectable products |
| Antibody-Drug Conjugates (ADC) | Commercial ADC manufacturing |
| Cell & Gene Therapy Services | Manufacturing support for advanced therapies |
| Laboratory Testing | Analytical testing, quality control, stability studies |
These integrated services allow clients to move from early-stage development to commercial manufacturing with a single CDMO partner.
Manufacturing Scale Creates a Competitive Advantage
Samsung Biologics has invested aggressively in manufacturing infrastructure.
The company now operates 845,000 liters of biologics manufacturing capacity, making it one of the largest biologics production networks globally. Plants 1 through 4 are fully operational, while Plant 5 has begun contributing to revenue in 2026.
To strengthen its global footprint, Samsung Biologics also expanded into the United States through the acquisition of a manufacturing facility in Rockville, Maryland, adding approximately 60,000 liters of production capacity. This investment improves supply-chain resilience and brings manufacturing closer to major pharmaceutical customers.
Sales Growth Continues to Accelerate
Samsung Biologics has maintained a remarkable revenue trajectory over the past six years.
| Year | Revenue (KRW Trillion) |
|---|---|
| 2020 | 1.165 |
| 2021 | 1.568 |
| 2022 | 2.437 |
| 2023 | 2.939 |
| 2024 | 3.497 |
| 2025 | 4.557 |
Revenue has nearly quadrupled since 2020, demonstrating the company’s ability to consistently secure new manufacturing contracts while increasing utilization across existing facilities.
Regulatory Strength Supports Long-Term Growth
Regulatory compliance is a major differentiator in biologics manufacturing.
Samsung Biologics has accumulated more than 420 global regulatory approvals, including inspections and certifications from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Japan’s PMDA, and other international health authorities. This strong compliance record helps attract multinational pharmaceutical companies seeking reliable manufacturing partners.
Strategic Analysis
Samsung Biologics’ business model is built on high-value manufacturing rather than direct drug sales. This allows the company to benefit from the expansion of biologics across multiple therapeutic areas without assuming the clinical development risks faced by pharmaceutical innovators.
Its combination of large-scale manufacturing capacity, advanced technology platforms, strong regulatory compliance, and long-term customer contracts has created significant barriers to entry. Continued investments in ADC manufacturing, drug product capabilities, and U.S. production facilities further strengthen its competitive position.
The company is also well positioned to benefit from government initiatives that encourage domestic biologics production and more resilient pharmaceutical supply chains in the United States, Europe, and Asia.
Forecast
Samsung Biologics is expected to remain one of the fastest-growing global CDMOs over the next five years. With management projecting 15–20% revenue growth in 2026, expanding manufacturing capacity, cumulative contract value exceeding USD 21.4 billion, and increasing demand for biologics, biosimilars, and advanced therapies, the company is positioned for sustained double-digit growth. Its expanding service portfolio, operational efficiency, and global manufacturing network are likely to support continued revenue expansion and strengthen its leadership in outsourced biopharmaceutical manufacturing.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium